Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the of Surgeons Oncology Group. Novartis supplied Gleevec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Gleevec.

Gleevec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit- positive GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Gleevec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... has demonstrated that Induction Chemotherapy prior to ... to standard ChemoRadiotherapy alone -MADRID, May 30 ... Cooperative Group (TTCC) announced today that Induction ... (CRT), a treatment paradigm defined as sequential ...
... GlaxoSmithKline [NYSE: GSK] and Genmab A/S [OMX: ... and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee ... (ofatumumab) data are reasonably likely to predict clinical ... whose disease is refractory to fludarabine and alemtuzumab. ...
Cached Medicine Technology:Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 2Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5
(Date:12/22/2014)... recognition of Veteran’s Day, Discount Labels contributed a portion ... that provides services to veterans and their families, free ... hundred acres in the hills of Southern Indiana, the ... hiking, horseback riding, 4-wheeling, skeet shooting, and much more. ... U.S. Service men and women, police officers, fire fighters ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, Dr. Marine ... drivers are 15 times more likely to cause deadly ... experts believe that sleep-deprived drivers may be just as ... of Americans may be sleep-deprived without even knowing it. ... 18 million Americans have sleep apnea, but as many ...
(Date:12/22/2014)... 22, 2014 7,178 small business owners ... Black Friday shopping and opted instead to join Digital ... company, for their 5th annual “Black Friday Boot Camp”. ... $7 to attend the 5 hour online training event ... donated to support two Central Texas based charities dedicated ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. Ms. Foley is recognized with ... largest, most-recognized networking organization of professional women in the ... Association of Professional Women is a powerfully vibrant networking ... Chapters. , “As a nurse, I felt like I ...
Breaking Medicine News(10 mins):Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... benefit from liver supportive liver therapy while ... to enable bridging to liver transplantation. Albumin ... and renal function as well as the ... hemodynamic alterations in stable patients with cirrhosis ...
... Digestive Disease Week (DDW), SAN DIEGO, May ... Disease Week meeting that showed Cimzia(R) (certolizumab pegol),provided ... than 60 percent,of Crohn,s disease patients who were ... percent of patients achieved remission by six weeks.,Data ...
... Depression is a serious,but treatable health condition that ... be the focus of a national campaign during Mental,Health ... is,supported by the Anthem Blue Cross Foundation, the charitable ... Depression National Awareness Campaign is an effort to,increase knowledge, ...
... to introduce local physicians to new facility, SAN CARLOS, ... of its newest facility in San Carlos, welcoming doctors,located within ... was on hand to mingle with guests and provide tours ... were in attendance to learn about,SleepQuest,s services and the benefits ...
... Ltd. (Amex: CPD ) announced that the ... fiscal year 2008 ended March 31, 2008,prior to ... Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets ... largest wholesalers, distributors,drugstore chains and managed care providers., ...
... find tissue that normally lines the stomach in locations outside ... identified in such diverse locations as the scrotum, the gall ... a team led by Dr. Steven Paul Schmidt, is described ... of Gastroenterology. , Typically, when this gastric tissue is located ...
Cached Medicine News:Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 2Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 3Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 4Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 5Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 6Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 7Health News:Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients 8Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 2Health News:Anthem Blue Cross Foundation Supports National Campaign Focused on Depression Among Men 3Health News:SleepQuest Holds Open House 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008 2Health News:Heterotopic gastric tissue simulating acute appendicitis 2
... these recommendations with the exceptional design and ... resulted in numerous improvements, such as:, ... holder for hassle-free storage , The system ... a flick of the lever, making transportation ...
The S4 Spinal System has quickly gained a reputation for being the next generation in pedicle screw systems because of its exceptionally small size and high biomechanical strength....
... Diagnostics is a clinical reference ... treatment and monitoring of hemostatic ... a collaboration of four laboratory ... defined vision to deliver customizable ...
All-natural porcine collagen can be used in open or laparoscopic placement....
Medicine Products: